Ezetimibe Promotes CYP7A1 and Modulates PPARs As a Compensatory Mechanism in LDL Receptor-deficient Hamsters

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2020 Feb 10

PMID 32035489

Citations 6

Authors

Bin Xia

Ping Lin

Yubin Ji

Jiayu Yin

Jin Wang

Xiaoqian Yang

Ting Li

Zixun Yang

Fahui Li

Shoudong Guo

Affiliations

Soon will be listed here.

Abstract

Background: The LDL-C lowering effect of ezetimibe has been attributed primarily to increased catabolism of LDL-C via up-regulation of LDL receptor (LDLR) and decreased cholesterol absorption. Recently, ezetimibe has been demonstrated to have reverse cholesterol transport (RCT) promoting effects in mice, hamsters and humans. However, the underlying mechanisms are still not clear. The aim of this study is to investigate whether ezetimibe improves RCT-related protein expression in LDLR hamsters.

Methods: A high-fat diet was used to induce a human-like hyperlipidemia in LDLR hamsters. Lipid profiles were assayed by commercially available kits, and the effects of ezetimibe on lipid metabolism-related protein expression were carried out via western blot.

Results: Our data demonstrated that ezetimibe administration significantly reduced plasma total cholesterol (~ 51.6% reduction, P < 0.01) and triglyceride (from ~ 884.1 mg/dL to ~ 277.3 mg/dL) levels in LDLR hamsters fed a high-fat diet. Ezetimibe administration (25 mg/kg/d) significantly promoted the protein expression of cholesterol 7 alpha-hydroxylase A1 (CYP7A1), LXRβ and peroxisome proliferator-activated receptor (PPAR) γ; and down-regulated the protein expression of PPARα and PPARβ. However, it showed no significant effect on sterol regulatory element-binding protein (SREBP)-1c, SREBP-2, proprotein convertase subtilisin/kexin type 9 (PCSK9), Niemann-Pick C1-like 1 (NPC1L1), and ATP-biding cassette (ABC) G5/G8.

Conclusion: Ezetimibe may accelerate the transformation from cholesterol to bile acid via promoting CYP7A1 and thereby enhance RCT. As a compensatory mechanism of TG lowering, ezetimibe promoted the protein expression of PPARγ and decreased PPARα and β. These results are helpful in explaining the lipid-lowering effects of ezetimibe and the potential compensatory mechanisms.

Citing Articles

Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase....

Su Q, Liu Y, Zhang G, Xu L, Wang M, Mei S Adv Ther. 2023; 40(12):5285-5299.

PMID: 37770770 PMC: 10611639. DOI: 10.1007/s12325-023-02666-z.

Hypolipidemic effect of ethanol extract from Chimonanthus nitens Oliv. leaves in hyperlipidemia rats via activation of the leptin/JAK2/STAT3 pathway.

Pan J, Ouyang X, Jin Q, Wang W, Xie J, Yu B Mol Med. 2022; 28(1):159.

PMID: 36539694 PMC: 9768954. DOI: 10.1186/s10020-022-00589-z.

iTRAQ Quantitative Proteomic Analysis of Different Expressed Proteins and Signal Pathways in Bakuchiol-Induced Hepatotoxicity.

Gao S, Xu D, Abulizi A, Maimaiti Y, Aibai S, Jiang Z Evid Based Complement Alternat Med. 2022; 2022:2928240.

PMID: 36193146 PMC: 9526664. DOI: 10.1155/2022/2928240.

Ezetimibe and Cancer: Is There a Connection?.

Gu J, Zhu N, Li H, Zhang C, Gong Y, Liao D Front Pharmacol. 2022; 13:831657.

PMID: 35924044 PMC: 9340271. DOI: 10.3389/fphar.2022.831657.

Polysaccharide CM1 from Cordyceps militaris hinders adipocyte differentiation and alleviates hyperlipidemia in LDLR hamsters.

Yu W, Yin F, Shen N, Lin P, Xia B, Li Y Lipids Health Dis. 2021; 20(1):178.

PMID: 34895241 PMC: 8667404. DOI: 10.1186/s12944-021-01606-6.

References

Wang Y, Liu X, Pijut S, Li J, Horn J, Bradford E . The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination. J Lipid Res. 2015; 56(4):810-20. PMC: 4373739. DOI: 10.1194/jlr.M053454. View

Temel R, Tang W, Ma Y, Rudel L, Willingham M, Ioannou Y . Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007; 117(7):1968-78. PMC: 1888567. DOI: 10.1172/JCI30060. View

Yu X, Zhang D, Zheng X, Tang C . Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. Prog Lipid Res. 2018; 73:65-91. DOI: 10.1016/j.plipres.2018.12.002. View

Sabeva N, Liu J, Graf G . The ABCG5 ABCG8 sterol transporter and phytosterols: implications for cardiometabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009; 16(2):172-7. PMC: 4097028. DOI: 10.1097/med.0b013e3283292312. View

Altemus J, Patel S, Sehayek E . Liver-specific induction of Abcg5 and Abcg8 stimulates reverse cholesterol transport in response to ezetimibe treatment. Metabolism. 2014; 63(10):1334-41. DOI: 10.1016/j.metabol.2014.06.014. View

van Heek M, Farley C, Compton D, Hoos L, Davis H . Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001; 134(2):409-17. PMC: 1572957. DOI: 10.1038/sj.bjp.0704260. View

Xie P, Jia L, Ma Y, Ou J, Miao H, Wang N . Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2013; 33(5):920-5. PMC: 3965670. DOI: 10.1161/ATVBAHA.112.301187. View

Davidson M, Voogt J, Luchoomun J, Decaris J, Killion S, Boban D . Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 2013; 230(2):322-9. DOI: 10.1016/j.atherosclerosis.2013.08.006. View

Guo S, Tian H, Dong R, Yang N, Zhang Y, Yao S . Exogenous supplement of N-acetylneuraminic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2016; 251:183-191. DOI: 10.1016/j.atherosclerosis.2016.05.032. View

10.

Guo X, Gao M, Wang Y, Lin X, Yang L, Cong N . LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis. EBioMedicine. 2018; 27:214-224. PMC: 5828369. DOI: 10.1016/j.ebiom.2017.12.013. View

11.

Wang J, He K, Yang C, Lin X, Zhang X, Wang Y . Dietary Cholesterol Is Highly Associated with Severity of Hyperlipidemia and Atherosclerotic Lesions in Heterozygous LDLR-Deficient Hamsters. Int J Mol Sci. 2019; 20(14). PMC: 6678973. DOI: 10.3390/ijms20143515. View

12.

Zhong C, Sun W, Ma Y, Zhu H, Yang P, Wei H . Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice. Sci Rep. 2015; 5:10512. PMC: 4444975. DOI: 10.1038/srep10512. View

13.

Briand F, Naik S, Fuki I, Millar J, Macphee C, Walker M . Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci. 2010; 2(2):127-33. PMC: 2823289. DOI: 10.1111/j.1752-8062.2009.00098.x. View

14.

Yang Z, Liu G, Wang Y, Yin J, Wang J, Xia B . Fucoidan A2 from the Brown Seaweed Ascophyllum nodosum Lowers Lipid by Improving Reverse Cholesterol Transport in C57BL/6J Mice Fed a High-Fat Diet. J Agric Food Chem. 2019; 67(20):5782-5791. DOI: 10.1021/acs.jafc.9b01321. View

15.

Ouimet M, Barrett T, Fisher E . HDL and Reverse Cholesterol Transport. Circ Res. 2019; 124(10):1505-1518. PMC: 6813799. DOI: 10.1161/CIRCRESAHA.119.312617. View

16.

Temel R, Brown J . Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol. 2012; 23(2):85-90. PMC: 3711548. DOI: 10.1097/MOL.0b013e3283508c21. View

17.

Garcia-Calvo M, Lisnock J, Bull H, Hawes B, Burnett D, Braun M . The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005; 102(23):8132-7. PMC: 1149415. DOI: 10.1073/pnas.0500269102. View

18.

Uto-Kondo H, Ayaori M, Sotherden G, Nakaya K, Sasaki M, Yogo M . Ezetimibe enhances macrophage reverse cholesterol transport in hamsters: contribution of hepato-biliary pathway. Biochim Biophys Acta. 2014; 1841(9):1247-55. DOI: 10.1016/j.bbalip.2014.05.009. View

19.

Yin J, Wang J, Li F, Yang Z, Yang X, Sun W . The fucoidan from the brown seaweed Ascophyllum nodosum ameliorates atherosclerosis in apolipoprotein E-deficient mice. Food Funct. 2019; 10(8):5124-5139. DOI: 10.1039/c9fo00619b. View

20.

Jakulj L, van Dijk T, de Boer J, Kootte R, Schonewille M, Paalvast Y . Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion. Cell Metab. 2016; 24(6):783-794. DOI: 10.1016/j.cmet.2016.10.001. View